(Q37453614)

20 August 2017

1 reference

title

Exenatide: a review from pharmacology to clinical practice (English)

1 reference

20 August 2017

1 reference

R Gentilella

1

1 reference

20 August 2017

C Bianchi

series ordinal

2

1 reference

20 August 2017

A Rossi

series ordinal

3

1 reference

20 August 2017

C M Rotella

series ordinal

4

1 reference

20 August 2017

publication date

5 April 2009

1 reference

Diabetes, Obesity and Metabolism

20 August 2017

published in

1 reference

20 August 2017

volume

11

1 reference

20 August 2017

issue

6

1 reference

20 August 2017

page(s)

544-556

1 reference

Glucagon-like peptide 1 (GLP-1) and metabolic diseases

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2008.01018.X

Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2008.01018.X

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2008.01018.X

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2008.01018.X

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2008.01018.X

10.1111/J.1463-1326.2008.01018.X

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference